The most common frontline treatment for diffuse large B cell lymphoma (DLBCL) is cyclophosphamide, doxorubicin, vincristine sulfate, and prednisone (CHOP). However, approximately 1 in 3 patients relapse after CHOP, and alternative therapies are still needed.
According to Jason Westin, MD, the leader of the DLBCL research team at the University of Texas MD Anderson Cancer Center, the strategies for DLBCL treatment have not changed drastically since the mid 1970s. Additionally, more information is needed as to why patients relapse after CHOP.
For patients who are CHOP resistant, the standard of care is strong chemotherapy followed by an autologous stem cell transplant. However, according to Westin, more personalized and targeted therapies are needed.
In an interview with Targeted OncologyTM, Westin discussed the future of DLBCL treatment in both the frontline and later-line settings, along with current unmet clinical needs.
TARGETED ONCOLOGY: Can you give a background on current treatments in DLBCL?
WESTIN: DLBCL is the most common lymphoid cancer in adults, it's diagnosed in about 30,000 people each year in the US. And the treatments of that most common lymphoid cancer have been effectively stuck in the 1970s and the 1990s. We use a combination chemotherapy approach called CHOP, which was originally prescribed in 1976. We've changed a lot in life from 1976 to now, but we're still using this old combination chemotherapy in the curative setting for lymphoma. So obviously, new approaches are needed.
What does the current DLBCL treatment landscape?
Most patients are treated with the combination chemotherapy CHOP, and that cures approximately 2/3 of patients. It's a fairly effective standard therapy. However, at least 1 out of 3 people need additional treatments, and we don't do as well in the relapse setting as we'd like. So, we're constantly trying to innovate and improve that frontline setting and get beyond the 2/3 cure rate with initial treatments, and that will take a better understanding of why those 1/3 don't respond to CHOP, and a better understanding of the biology of what makes them resistant to treatments.
Do we know anything right now about the mechanisms of resistance to CHOP?
We know some, but I argue that we don't nearly know as much as we think we do. We understand the biology in the sense of understanding which mutation is present, or what type of gene signature. But often, the actual reason as to why a given patient doesn't respond to CHOP is very poorly understood. Patients that have the same biopsy, same genetic signature, some of those patients are cured and some of those patients are resistant. And it's difficult to predict prior to therapy which of those patients are resistant.
For patients that are resistant to CHOP, what options exist for them?
The standard of care for the past 20 years for those resistant to CHOP has been strong chemotherapy followed by an autologous stem cell transplant. Beyond the second line setting right now, there are a number of FDA approved agents for patients with relapsed BLBCL, and many of those FDA approved agents are being studied in combination CHOP and rituximab [Rituxan; R-CHOP].
What clinical needs are still unmet in this patient population?
The needs that are still unmet are finding more personalized therapies, specifically for those patients who are not cured with R-CHOP. But I would argue even in those patients who are currently cured with R-CHOP, that we don't want to use 1970s, chemotherapy in 2050. We want to be able to have personalized approaches and be able to move beyond effectively sledgehammer kind of blunt force instruments and use more precision medicine. So, we clearly need to do better urgently for the folks who are currently resistant or not responsive to chemotherapy. But I'd argue in the long run we need to do better across the board.
Do you see more aggressive approaches like autologous stem cell transplant and targeted therapies moving to the frontline setting in the future? Or do you think they'll remain a second- and third-line option?
I think that CAR T cells have the potential to move to the frontline for a subset of patients, for those that are not going to be responsive to our standard treatments. I think that's an approach that has merit, to try and use a powerful weapon at an earlier time point. I don't think stem cell transplant will do that. But I do think some of the other targeted therapies, the antibody drug conjugates, the bispecific antibodies, antibodies in combination with other immune therapies do potentially have a role to play in the frontline setting.
Where do you see the DLBCL space going in the next 5 to 10 years?
Well, I'd love to say things will be dramatically different. But we could have said that at any point over the last 20 years and would have been wrong. There are multiple ongoing studies looking at ways to improve the frontline setting. But innovation is more likely in the relapse space, which then filters up to the frontline space. And I think that the CAR T-cell studies showing potential advantages in the second line will change the landscape for patients who have relapsed after R-CHOP in the next 5 to 10 years to favor using CAR T-cell therapy. I think based on having that better cure fraction in the relapse space, more innovation may be possible in the frontline space. And so therefore doing studies that are not handcuffed to the 1970s chemotherapy for fear of not giving a patient the old curative therapy and missing a potential window for cure, I think that will allow us to do more innovative studies. I've done a handful of clinical trials using targeted therapy combinations prior to chemotherapy. And what we've shown in those studies is the response rates are very high. And patients tolerate it very well. And so that's still on a clinical trial stage. But it does show the potential that these targeted treatments can work better in newly diagnosed patients and potentially forego the need for chemotherapy.
I think the R-CHOP plus combination trial designs a failure. And I think that more innovative trial designs are needed. But clinical research still remains the best weapon we have to fight cancer in general and specifically DLBCL.
Go here to read the rest:
Newer Agents for DLBCL Show Potential for Earlier Use in the Course of Treatment - Targeted Oncology
- NIH researchers develop first stem cell model of albinism to study related eye conditions - National Institutes of Health - January 16th, 2022
- Exploring the relationship between stem cells and COVID-19 - News-Medical.Net - January 16th, 2022
- Trial of Cell Therapy to Raise HbF Levels Showing Potential, But... - Sickle Cell Anemia News - January 16th, 2022
- Nowakowski Considers CD19 Therapy in Transplant-Ineligible DLBCL - Targeted Oncology - January 16th, 2022
- More info needed to recommend nonembryo stem cell treatments - Oil City Derrick - January 16th, 2022
- Impact of Cancer Stem Cells and Cancer Stem Cell-Driven Drug Resiliency in Lung Tumor: Options in Sight - Newswise - January 16th, 2022
- Clonal evolution in patients developing therapy-related myeloid neoplasms following autologous stem cell transplantation - DocWire News - January 16th, 2022
- Severe Combined Immunodeficiency Treatment Market: Availability of Drugs and Immune-related Treatments Are Anticipated to Drive the Global Market -... - January 16th, 2022
- Cell and Gene Therapy Business Outlook Service - Yahoo Finance - January 16th, 2022
- 5 questions facing gene therapy in 2022 - BioPharma Dive - January 16th, 2022
- Bayer Strikes "Mammoth" CRISPR Deal to Bolster Cell and Gene Therapy - BioSpace - January 16th, 2022
- Outsmarting Cancer: Next Generation Therapies - BioSpace - January 16th, 2022
- The Fusion of mRNA and Immunotherapy - NEO.LIFE - January 16th, 2022
- Pain In The Shoulder? Reasons Why You Shouldn't Shrug It Off - TheHealthSite - January 16th, 2022
- ASU Biodesign Institute receives $5.2M from Michael J. Fox Foundation to advance fight against Parkinson's - Arizona State University - January 16th, 2022
- I Am Very Lucky That These Days Are Not Painful for Me, Says MS Fighter Selma Blair as She Shares an Update Amid IVIG Treatment; Making Time for... - January 16th, 2022
- Popular Erie bowler, recovering from leukemia, excited to compete in Times-News Open - GoErie.com - January 16th, 2022
- They wanted to cure heart disease. They discovered a way to grow a different kind of muscle - Haaretz - January 16th, 2022
- Christina Applegate says it's 'sad' she and 'The Sweetest Thing' co-star Selma Blair both have MS - Yahoo News - January 16th, 2022
- Private cord blood bank CellSave Arabia receives the first DHA license to operate as a Cord Blood and Stem Cell Center - Gulf News - January 16th, 2022
- Therapeutic Solutions International Successfully Treats No Option Patients with its JadiCell Stem Cell Therapy While Advancing Preparations for Phase... - January 2nd, 2022
- Exclusive: Ronnie Coleman on Recent Weight Gain, Current Strength, and Health Progress - BarBend - January 2nd, 2022
- Mesenchymal stem/stromal cell-based therapies for severe viral pneumonia: therapeutic potential and challenges - DocWire News - January 2nd, 2022
- Brainstorm Cell Therapeutics (BCLI) Receives FDA Authorization for Expanded Dosing Program; Shares Higher - InvestorsObserver - January 2nd, 2022
- Cell Freezing Media for Cell Therapy Market Size 2021 Analysis by Top Companies | Biolife Solutions,Thermo Fisher Scientific,Merck,Ge Healthcare ... - January 2nd, 2022
- Stem Cell Treatment Improves Type 1 Diabetes in 1 Patient - Everyday Health - December 23rd, 2021
- Avra, Inc. Completes its Merger with Springs Rejuvenation, LLC, a Stem Cell and Anti-Aging Treatment Company - GlobeNewswire - December 23rd, 2021
- Global Regenerative Medicine Market is Expected to Reach USD 57.08 Billion by 2027, Growing at a CAGR of 11.27% Over the Forecast Period. -... - December 23rd, 2021
- Importance of stem cells-Past, present and future - Express Healthcare - December 23rd, 2021
- Stem cell therapy holds immense promise for the treatment of patients with non-healing ischemic leg wounds - Ibcworldnews - December 23rd, 2021
- BioRestorative Therapies, Inc. Releases Year-End Message - BioSpace - December 23rd, 2021
- Corneal epithelial differentiation of human pluripotent stem cells generates ABCB5+ and Np63+ cells with limbal cell characteristics and high wound... - December 23rd, 2021
- Receiving CAR-T therapy sooner improves lymphoma survival, according to study published in New England Journal of Medicine - Newswise - December 23rd, 2021
- Cell Therapy Market becoming larger and Massively Growing up with CAGR of 25.6% mainlander.nz - mainlander.nz - December 23rd, 2021
- City of Hope presents leading-edge research on blood cancer therapies and its vaccine to reduce stem cell transplant complications at American Society... - December 23rd, 2021
- This Startup Is Makingand ProgrammingHuman Cells - WIRED - December 23rd, 2021
- Daiichi Sankyo Authorizes the First YESCARTA (Axicabtagene Ciloleucel) CAR T-cell Therapy Treatment Site in Japan - Business Wire - December 23rd, 2021
- Communication between cells plays a major role in deciding their fate > News > USC Dornsife - USC Dornsife College of Letters, Arts and Sciences - December 23rd, 2021
- Emendo Biotherapeutics and Seattle Childrens Research Institute Announce Collaboration to Develop CRISPR-based Therapeutic Strategy for Severe... - December 23rd, 2021
- National Advertising Division Recommends Cryo-Cell Discontinue or Modify Certain Health-Related Claims for Cord Blood Banking and Treatment Services -... - December 23rd, 2021
- Systemic Mastocytosis Treatments Gain Hope Due To Increasing Novel Treatment Options - PRNewswire - December 23rd, 2021
- Seven tech trends to watch in 2022 | The Star - Toronto Star - December 23rd, 2021
- Seven tech trends to watch in 2022 | ThePeterboroughExaminer.com - ThePeterboroughExaminer.com - December 23rd, 2021
- Stem Cell Therapy: Alternative Treatment to Hip & Knee ... - November 22nd, 2021
- How The Overlap Between Artificial Intelligence And Stem Cell Research Is Producing Exciting Results - Forbes - November 22nd, 2021
- Selma Blair Posts Nude Diving Photo After MS Stem Cell ... - November 22nd, 2021
- Stem Cell Therapy Reduces Need for Nearly 10% of Hip Replacements - Yale School of Medicine - November 22nd, 2021
- Stem cell therapy for heart failure lowers risk of adverse outcomes - Cardiovascular Business - November 22nd, 2021
- A second HIV patient may have been 'cured' of infection without stem cell treatment, in extremely rare case - CNN - November 22nd, 2021
- The Promise of Stem Cells to Help Children with Autism - Entrepreneur - November 22nd, 2021
- Global Cell Therapy Manufacturing Market Competition Forecast & Opportunities to 2026 - ResearchAndMarkets.com - Galveston County Daily News - November 22nd, 2021
- Dr Pengyi Yang wins National Stem Cell Foundation Metcalf Prize - News - The University of Sydney - November 22nd, 2021
- BioRestorative Therapies Enters into Letter of Intent with PRC Clinical - BioSpace - November 22nd, 2021
- SC21- 21st century cellular medicines specialists - The Thaiger - November 22nd, 2021
- From asthma to cancer to infertility, the new treatments, jabs and meds making us healthier... - The Sun - November 22nd, 2021
- New hope for bowel cancer patients as fresh partnership between Carina Biotech and CellVec enables advancement of clinical trials. - Bio-IT World - November 22nd, 2021
- FDA Approves Merck's KEYTRUDA (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery - Business... - November 22nd, 2021
- Mum with brain fog and pins and needles in hands devastated by 'ticking time bomb' MS - Mirror.co.uk - November 22nd, 2021
- CAR T-cell therapy: Hear from a Canadian patient - CTV News - November 8th, 2021
- Talaris therapy ends need for immune drugs in transplant patients - - pharmaphorum - November 8th, 2021
- Treatment Sequencing Could Change With Complementary Combinations and CAR T Options in B-ALL - OncLive - November 8th, 2021
- Parkinson's gene therapy restores responses to dopamine-boosting drug in mouse models - FierceBiotech - November 8th, 2021
- Studies: CAR-T therapies superior to standard treatment in blood cancer - STAT - November 8th, 2021
- Salit Discusses the Use of Staging and Grading for Patients With GVHD to Choose Appropriate Treatment - Targeted Oncology - November 8th, 2021
- Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Updates - BioSpace - November 8th, 2021
- Global Stem Cell Therapy Market Size, Analytical Overview, Growth Factors, Demand, Trends and Forecast to 2026 - Northwest Diamond Notes - November 8th, 2021
- BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting &... - November 8th, 2021
- CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results - Yahoo Finance - November 8th, 2021
- Bacterial Infections Linked with Unapproved Stem Cell Treatments - Contagionlive.com - October 28th, 2021
- Team finds way to enhance stem cell therapy for CNS injuries - BioPharma-Reporter.com - October 28th, 2021
- Stem cell therapy can help combat common symptoms of aging - The Mountaineer - October 28th, 2021
- Stem Cells Used to Treat Avascular Necrosis of the Femoral Head - Yale School of Medicine - October 28th, 2021
- Vitti Labs Announces FDA Approval of IND Application for Phase II Clinical Trial of Combination Mesenchymal Stem Cell and Exosome Treatment of Novel... - October 28th, 2021
- Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM (Antibody Recruiting Molecule) Platform, in Combination with NK Cell... - October 28th, 2021
- The Power of the Immune System: New Treatment for Painful Blood Cancer Side Effect - Curetoday.com - October 28th, 2021
- Global Cell Therapy Market Research Report 2021: Opportunities with the Approval of Kymriah and Yescarta Across Various Countries -... - October 28th, 2021
- Pursuing Optimal Therapy Remains a Challenge in Indolent B-Cell Lymphoma - Targeted Oncology - October 28th, 2021
- Stem Cell Therapy Market Research Report by Cell Source, by Type, by Therapeutic Application, by End-User, by Region - Global Forecast to 2026 -... - October 16th, 2021
- Harvard's R&D alliance with Resilience to advance manufacture of complex medicines - Harvard Gazette - October 16th, 2021
- A New Line of Defense in Blood Cancer: Natural Killer Cell Therapy - Curetoday.com - October 16th, 2021